


Accepted Manuscript

HDAC11 is a regulator of diverse immune functions

Cansu Yanginlar, Colin Logie



PII: S1874-9399(17)30374-7
DOI: doi:[10.1016/j.bbagr.2017.12.002](https://doi.org/10.1016/j.bbagr.2017.12.002)
Reference: BBAGRM 1199

To appear in:

Received date: 1 November 2017
Revised date: 2 December 2017
Accepted date: 2 December 2017

Please cite this article as: Cansu Yanginlar, Colin Logie , HDAC11 is a regulator of diverse immune functions. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Bbagrm(2017), doi:[10.1016/j.bbagr.2017.12.002](https://doi.org/10.1016/j.bbagr.2017.12.002)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

HDAC11 is a regulator of diverse immune functions

Cansu Yanginlar, Colin Logie*

Department of Molecular Biology, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands

* Corresponding author. Tel.: +31 243610525; Fax: +31 243610520. E-mail: c.logie@science.ru.nl

Histone deacetylases deacetylate histone and non-histone protein targets. Aberrant HDAC expression and function have been observed in several diseases, which makes these enzymes attractive treatment targets. Here, we summarize recent literature that addresses the roles of HDAC11 on the regulation of different immune cells including neutrophils, myeloid derived suppressor cells and T-cells. HDAC11 was initially identified as a negative regulator of the well-known anti-inflammatory cytokine IL-10. Hence, antagonizing HDAC11 activity may have anti-tumor potential, whereas activating HDAC11 may be useful to treat chronic inflammation or autoimmunity. However, to anticipate biological side-effects of HDAC11 modulators, more molecular insights will be required.

Keywords: HDAC11, epigenetics, immune system, HDACi

Abbreviations: APC, antigen presenting cell; CTCL, cutaneous T-cell lymphoma; DAMP, damage associated molecular pattern; DC, dendritic cell; FDA, U.S. food and drug administration; GVHD, graft versus host disease; HAT, histone acetyltransferase; HDAC, histone deacetylase; HDACi, histone deacetylase inhibitor; HEK293, human embryonic kidney cells 293; IFN, interferon; IL, interleukin; miR145, microRNA 145; MDSC, myeloid derived suppressor cell; GO, gene ontology; PAMP, pathogen associated molecular pattern; PTCL, peripheral T-cell lymphoma; SAHA, suberoylanilide hydroxamic acid; siRNA, small interfering RNA; TcR, T cell receptor; Treg, regulatory T cell; TNF- α , tumor necrosis factor α ; UTR, untranslated region.

Download English Version:

<https://daneshyari.com/en/article/8300423>

Download Persian Version:

<https://daneshyari.com/article/8300423>

[Daneshyari.com](https://daneshyari.com)